Apoptosis pathway-targeted drugs - from the bench to the clinic

被引：69

作者：

Cummings, J ^{[1
]}

Ward, TH ^{[1
]}

Ranson, M ^{[1
]}

Dive, C ^{[1
]}

机构：

[1] Paterson Inst Canc Res, Canc Res UK, Clin & Expt Pharmacol Grp, Manchester M20 4BX, Lancs, England

来源：

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2004年 / 1705卷 / 01期

关键词：

apoptosis-targeted therapy; early clinical trial; quality assurance; assay validation; biomarker; pharmacodynamic assay;

D O I：

10.1016/j.bbcan.2004.09.005

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

It is an exciting time for cancer researchers in the field of apoptotic cell death. The avalanche of discoveries over the past decade or so regarding how apoptosis is regulated begins to be exploited for therapeutic benefit as the first apoptosis-targeted drugs enter early clinical trials. This chapter provides a selective review on the development of such drugs. We also outline issues regarding the regulation and design of early clinical trials of this type of molecularly targeted agent. Finally, we discuss the biomarkers and surrogate pharmacodynamic endpoint assays currently available to chart the efficacy of apoptosis-inducing anticancer therapy. (C) 2004 Elsevier B.V. All rights reserved.

引用

页码：53 / 66

页数：14

共 146 条

[1] Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition [J].